Long term effect of Omalizumab on severe asthma Source: International Congress 2017 – Asthma management Year: 2017
Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Clinical benefits and safety of long term treatment with Montelukast in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
The effect of inhaled corticosteroids on the hypothalamic-pituitary-adrenal-axis in short term and long term treatment Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Functional effects of long term ICS treatment in controlled asthma Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011
Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015
Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018 Year: 2019
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020
Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018 Year: 2018
Effect of inhaled steroids on long term prognosis of lung function in adults with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 664s Year: 2004
Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Efficacy of the long-term therapy with simbicort in children with bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Impact of omalizumab treatment persistence on asthma control Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012